Search

Sita

Sita

sitagliptin

Manufacturer:

CCL Pharma

Distributor:

Manawhari
Concise Prescribing Info
Contents
Sitagliptin
Indications/Uses
As adjunct to diet & exercise to improve glycaemic control in patients w/ type 2 DM as monotherapy. Combination therapy w/ metformin or PPARγ agonist (ie, thiazolidinediones) as initial therapy or when diet & exercise do not provide adequate glycaemic control. Combination w/ sulfonylurea when treatment w/ the single agent alone does not provide adequate glycaemic control. Combination w/ metformin & a sulfonylurea or metformin & PPARγ agonist when dual therapy w/ these agents, w/ diet & exercise, does not provide adequate glycaemic control.
Click to view Sita detailed prescribing information
Dosage/Direction for Use
Monotherapy or as combination therapy w/ metformin, sulfonylurea, PPARγ agonist, metformin + sulfonylurea, metformin + PPARγ agonist 100 mg once daily. Patients w/ renal insufficiency: Moderate renal insufficiency (CrCl ≥30 to <50 mL/min) 50 mg once daily; severe renal insufficiency (CrCl <30 mL/min) or w/ end-stage renal requiring haemodialysis or peritoneal dialysis 25 mg once daily.
Click to view Sita detailed prescribing information
Overdosage
View Sita overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Click to view Sita detailed prescribing information
Special Precautions
Not to be used in patients w/ type 1 diabetes or treatment of diabetic ketoacidosis. Discontinue use if hypersensitivity reactions eg, anaphylaxis, angioedema & exfoliative skin conditions including Stevens-Johnson syndrome occur; or pancreatitis is suspected. Patients w/ renal insufficiency. Lower dosages are recommended in moderate & severe renal insufficiency, in ESRD patients requiring hemodialysis or peritoneal dialysis. Lower dose of sulfonylurea to reduce risk of sulfonylurea-induced hypoglycaemia. Pregnancy & lactation. Childn <18 yr. Elderly.   
Click to view Sita detailed prescribing information
Adverse Reactions
Abdominal pain, nausea, vomiting & diarrhea. Hypoglycemia; headache, upper resp tract infection, cough, fungal skin infection, peripheral oedema; dyspepsia, flatulence; asymptomatic decreased blood glucose.
Click to view Sita detailed prescribing information
Drug Interactions
Monitor patients receiving digoxin.
Click to view Sita detailed prescribing information
Storage
View Sita storage conditions for details to ensure optimal shelf-life.
Description
View Sita description for details of the chemical structure and excipients (inactive components).
Action
View Sita mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Sita FC tab 100 mg
Packing/Price
10 × 7's
Form
Sita FC tab 50 mg
Packing/Price
2 × 7's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in